Switch to:
Novo Nordisk A/S (NYSE:NVO)
Research and Development
$2,306 Mil (TTM As of Jun. 2014)

This is the expense the company spent on research and development. Novo Nordisk A/S's research and development for the three months ended in Jun. 2014 was $558 Mil. Its research and development for the trailing twelve months (TTM) ended in Jun. 2014 was $2,306 Mil.


Definition

This is the expense the company spent on research and development.

Novo Nordisk A/S Research & Development for the trailing twelve months (TTM) ended in Jun. 2014 was 511.342846689 (Sep. 2013 ) + 650.848695017 (Dec. 2013 ) + 586.015538291 (Mar. 2014 ) + 558.076225045 (Jun. 2014 ) = $2,306 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Novo Nordisk A/S Annual Data

Dec04Dec05Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13
Research & Development 7738251,1011,6911,3991,5071,7221,6721,9432,141

Novo Nordisk A/S Quarterly Data

Mar12Jun12Sep12Dec12Mar13Jun13Sep13Dec13Mar14Jun14
Research & Development 443423455572464476511651586558
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK